The methodology of calculation of sample size in "non-inferiority" comparative controlled clinical trials: a comparison of two proportions in parallel group

The absolute majority of clinical trials of generic drugs aimed to compare the therapeutic efficacy of the tested drug and the drug of an active control. It is necessary to estimate that the test drug is not less effective (or non-inferior) than the control drug. The designs of the aforementioned tr...

Full description

Saved in:
Bibliographic Details
Main Authors: A. A. Lyashenko (Author), M. S. Svishcheva (Author)
Format: Book
Published: Izdatelstvo OKI, 2018-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_fd5b0f7e39a8421ca76701a27ff937c1
042 |a dc 
100 1 0 |a A. A. Lyashenko  |e author 
700 1 0 |a M. S. Svishcheva  |e author 
245 0 0 |a The methodology of calculation of sample size in "non-inferiority" comparative controlled clinical trials: a comparison of two proportions in parallel group 
260 |b Izdatelstvo OKI,   |c 2018-06-01T00:00:00Z. 
500 |a 2588-0519 
500 |a 2618-8473 
520 |a The absolute majority of clinical trials of generic drugs aimed to compare the therapeutic efficacy of the tested drug and the drug of an active control. It is necessary to estimate that the test drug is not less effective (or non-inferior) than the control drug. The designs of the aforementioned trials are called "non-inferiority" study; often, these are phase III of clinical trials. The primary criterions of effectiveness which are quite often used in the clinical trials are frequencies of signs, as a result of the analysis of binary data. Binary data are analyzed by comparing proportions. One of the most important conditions for a correct interpretation of the data obtained during the clinical trials - to provide necessary and suffi cient sample size. The purpose of this article is to show how to plan the study, how to provide necessary and sufficient sample size to ensure that the results and conclusions would be reliable; how to interpret the data in a comparative controlled study aimed to establish "non­inferiority" using proportions comparing in parallel groups. 
546 |a RU 
690 |a клинические исследования 
690 |a исследования неменьшей эффективности 
690 |a граница неменьшей эффективности 
690 |a сравнитель­ные контролируемые исследования в параллельных группах 
690 |a доверительный интервал 
690 |a формула подсчёта выборки 
690 |a сравнение пропорций 
690 |a Medical technology 
690 |a R855-855.5 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Качественная клиническая практика, Vol 0, Iss 3, Pp 24-28 (2018) 
787 0 |n https://www.clinvest.ru/jour/article/view/369 
787 0 |n https://doaj.org/toc/2588-0519 
787 0 |n https://doaj.org/toc/2618-8473 
856 4 1 |u https://doaj.org/article/fd5b0f7e39a8421ca76701a27ff937c1  |z Connect to this object online.